Get the Stockscreener App
4.22
0.00%
0.00
Relmada Therapeutics Inc stock is traded at $4.22, with a volume of 431.37K.
It is up +0.00% in the last 24 hours and down -11.53% over the past month.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
See More
Previous Close:
$4.22
Open:
$4.28
24h Volume:
431.37K
Relative Volume:
0.25
Market Cap:
$452.81M
Revenue:
-
Net Income/Loss:
$-58.88M
P/E Ratio:
-3.7936
EPS:
-1.1124
Net Cash Flow:
$-42.79M
1W Performance:
+3.69%
1M Performance:
-11.53%
6M Performance:
-34.57%
1Y Performance:
+179.47%
1-Day Range:
$4.23
$4.39
1-Week Range:
$4.205
$4.65
52-Week Range:
$1.47
$8.00
Relmada Therapeutics Inc Stock (RLMD) Company Profile
Name
Relmada Therapeutics Inc
Sector
Industry
Phone
646 876 3459
Address
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
Compare RLMD vs MOBBW, PSNYW, GOODO, SHMD, CHAD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 3.03 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
1.35 | 2.19B | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
4.20 | 663.69M | 2.07B | -1.42B | -1.37B | -0.6765 |
GOODO
Gladstone Commercial Corporation
|
20.37 | 372.90M | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
3.50 | 222.94M | 52.15M | -21.46M | 0 | -0.4675 |
CHAD
Direxion Daily CSI 300 China A
|
8.80 | 197.39M | 0 | 0 | 0 | 0.00 |
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-24-26 | Initiated | Piper Sandler | Overweight |
| Jan-23-26 | Resumed | Leerink Partners | Outperform |
| Dec-22-25 | Initiated | Jefferies | Buy |
| Nov-19-25 | Upgrade | Mizuho | Neutral → Outperform |
| Dec-05-24 | Downgrade | Mizuho | Outperform → Neutral |
| Sep-17-24 | Upgrade | Jefferies | Hold → Buy |
| Jun-05-24 | Downgrade | Goldman | Neutral → Sell |
| Oct-14-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-14-22 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-14-22 | Downgrade | Truist | Buy → Hold |
| Oct-13-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-18-21 | Initiated | Mizuho | Buy |
| May-20-21 | Resumed | Goldman | Buy |
| Oct-28-20 | Downgrade | Goldman | Buy → Neutral |
| Jul-14-20 | Initiated | Oppenheimer | Outperform |
| May-04-20 | Initiated | SunTrust | Buy |
| Apr-21-20 | Initiated | Goldman | Buy |
| Jan-27-20 | Initiated | Jefferies | Buy |
| Jan-10-20 | Initiated | SVB Leerink | Outperform |
| Dec-16-19 | Initiated | Guggenheim | Buy |
View All
Relmada Therapeutics Inc Stock (RLMD) Latest News
RLMD Jumps As Executives Buy Shares And Signal Confidence - StocksToTrade
RLMD Jumps As Relmada Insider Buying Sparks Bullish Interest - StocksToTrade
RLMD Jumps As Relmada Insider Buying Sparks Bullish Focus - timothysykes.com
Relmada’s NDV-01 Bladder Cancer Trial Moves Into Phase 3: What Investors Should Watch - TipRanks
Relmada Therapeutics (RLMD) CFO Maged Shenouda Buys 200,000 Shar - GuruFocus
Relmada CEO Sergio Traversa buys 200,000 shares for $828,000 By Investing.com - Investing.com Nigeria
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Relmada Therapeutics CFO Maged Shenouda buys $843,990 in shares - Investing.com
Relmada Therapeutics Insiders Purchased Shares Worth Over $1.6M - TradingView
Relmada (NASDAQ: RLMD) CEO buys stock in two open-market trades - Stock Titan
Relmada Therapeutics (RLMD) CFO buys 200,000 shares in open market - Stock Titan
Relmada Therapeutics Announces Urology Chief Medical Officer Exit - TipRanks
Relmada Therapeutics (NASDAQ: RLMD) Announces Departure of CMO Dr. Raj S. Pruthi Effective September 3, 2026 - Kalkine Media
Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference - The Manila Times
Senior managers will hold one-on-one meetings in Boston at a Wells Fargo healthcare conference Sept. 8-10. - stocktitan.net
After Plunging 18.5% in 4 Weeks, Here's Why the Trend Might Reverse for Relmada Therapeutics (RLMD) - Yahoo Finance
Relmada Therapeutics (RLMD) Slides 4.2% to $4.33 as Clinical-Stage Pressures WeighAdvance Decline Line - vinanet.vn
Relmada Therapeutics Inc. (RLMD) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Relmada Therapeutics Inc. (RLMD) Key Financial Ratios – Valuation, Profitability & More - Value Research
Relmada Therapeutics (RLMD) Slips 0.87% as Shares Defend Support at $4.32Put Call Ratio - dars.gov.et
Here's Why Relmada Therapeutics (RLMD) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Relmada (RLMD) Chart: Moves 0.54% Down to $4.61 in the Latest Session; Levels: Price Remains Between $4.38 Support and $4.84 Resistance on the DayIchimoku Entry - siam.in
Relmada (RLMD) Results Breakdown: The Bottom-Line Figure Beats Its Comparison on the Day; Share Response: Shares Move Lower 0.22% in the Latest ReadingCost Structure Review - vinanet.vn
Relmada (RLMD) Q2 2026 Earnings Call Transcript - AOL.com
616,238 Shares in Relmada Therapeutics, Inc. $RLMD Acquired by Walleye Capital LLC - MarketBeat
Relmada Therapeutics (RLMD) gains 7.0% shareholder position from Squadron funds - Stock Titan
Relmada Therapeutics Earnings Call Highlights NDV-01 Path - TipRanks
Relmada Therapeutics Inc (RLMD) Stock Price, Trades & News - GuruFocus
Mizuho reiterates Relmada stock rating after manufacturing delay By Investing.com - Investing.com UK
Down 29.6% in 4 Weeks, Here's Why Relmada Therapeutics (RLMD) Looks Ripe for a Turnaround - Yahoo Finance
Equities Analysts Issue Forecasts for RLMD Q3 Earnings - marketbeat.com
Mizuho reiterates Relmada stock rating after manufacturing delay - Investing.com
Relmada Therapeutics (RLMD) Slides 7.6% to $4.57, Pressuring Key Support LevelSynthetic Long - dars.gov.et
Relmada Therapeutics (NASDAQ:RLMD) Posts Quarterly Earnings Results, Beats Expectations By $0.09 EPS - MarketBeat
Q2 2026 Relmada Therapeutics Inc Earnings Call Transcript - GuruFocus
Relmada Therapeutics (NASDAQ:RLMD) Stock Price Down 6.8%Time to Sell? - MarketBeat
Piper Sandler Maintains Relmada Therapeutics(RLMD.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Relmada Therapeutics Q2 Earnings Call Highlights - MarketBeat
Form 8K Relmada Therapeutics Inc For: 6 August By Investing.com - Investing.com Nigeria
Relmada Therapeutics (RLMD) Boosts Cash Reserves Ahead of Key IN - GuruFocus
Earnings call transcript: Relmada posts Q2 2026 EPS beat as shares slip - Investing.com Canada
Relmada Q2 2026 earnings: R&D spending rises ahead of planned IND filings - TradingKey
Relmada Therapeutics : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q) - marketscreener.com
RLMD: Strong cash position and robust NDV-01 phase II results set stage for late-stage trials in 2026 - TradingView
Relmada Highlights Q2 Results and NDV-01 Pipeline Progress - TipRanks
Relmada Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Relmada Reports Q2 Loss As Cash Balance Reaches $217.7 Million - Quiver Quantitative
Relmada Therapeutics (Nasdaq: RLMD) details Q2 2026 loss and NDV-01 Phase 3 path - Stock Titan
RELMADA THERAPEUTICS, INC. 2Q 2026: Net loss $12.9M, EPS $(0.11) — 10-Q Summary - TradingView
Relmada Therapeutics Inc Stock (RLMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Relmada Therapeutics Inc Stock (RLMD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Shenouda Maged | Chief Financial Officer |
Sep 10 '26 |
Buy |
4.25 |
79,800 |
339,150 |
1,000,000 |
| TRAVERSA SERGIO | Chief Executive Officer |
Sep 09 '26 |
Buy |
4.18 |
100,000 |
418,000 |
1,400,000 |
| TRAVERSA SERGIO | Chief Executive Officer |
Sep 10 '26 |
Buy |
4.10 |
100,000 |
410,000 |
1,500,000 |
| TRAVERSA SERGIO | Chief Executive Officer |
Dec 15 '25 |
Buy |
4.12 |
27,500 |
113,300 |
1,300,000 |
| Shenouda Maged | Chief Financial Officer |
Dec 15 '25 |
Buy |
4.12 |
11,665 |
48,060 |
800,000 |
| Shenouda Maged | Chief Financial Officer |
Nov 05 '25 |
Buy |
2.20 |
500,000 |
1,100,000 |
788,335 |
| Ence Chuck | CAO and COO |
Nov 05 '25 |
Buy |
2.20 |
136,000 |
299,200 |
403,931 |
| TRAVERSA SERGIO | Chief Executive Officer |
Nov 05 '25 |
Buy |
2.20 |
272,500 |
599,500 |
1,272,500 |
| Kelly Paul Edward | Chief Operating Officer |
Nov 05 '25 |
Buy |
2.20 |
90,000 |
198,000 |
502,295 |
0.35%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):